Filing Flows › Mimedx Group (MDXG) › Q2 2026 › vs Q1 2026
Mimedx Group (MDXG) Q2 2026 vs Q1 2026 (quarter over quarter)
Mimedx Group's revenue rose $5.4M (+9%) from $59.0M in Q1 2026 to $64.4M in Q2 2026. The biggest changes: Surgical +$2.9M (+8%); Wound +$2.4M (+11%).
Mimedx Group, Q2 2026: revenue $64.4M (-35% year over year), operating margin -28.7%, net loss $14.8M, operating cash flow −$10.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Surgical | $39.3M | $36.4M | $2.9M | +8% |
| Wound | $25.1M | $22.6M | $2.4M | +11% |
| Revenue | $64.4M | $59.0M | $5.4M | +9% |
| Other income, net | $686K | $718K | −$32K | -4% |
| Income tax benefit | $2.9M | $4.5M | −$1.5M | -34% |
| Net loss | $14.8M | $10.9M | $4.0M | +37% |
| Costs & expenses | $82.8M | $75.0M | $7.8M | +10% |
| Operating costs | $82.8M | $75.0M | $7.8M | +10% |
| Cost of revenue | $20.0M | $17.4M | $2.6M | +15% |
| Research & development | $2.8M | $4.1M | −$1.4M | -33% |
| Other operating costs | $291K | $301K | −$10K | -3% |
| Operating cash sources | $14.8M | $10.9M | $4.0M | +37% |
| Depreciation & amortization | $732K | $829K | −$97K | -12% |
| Share-based compensation | $903K | $0 | $903K | — |
| Working capital & other | $3.2M | $11.9M | −$8.7M | -73% |
| Cash used in operations | $10.0M | −$1.9M | $11.9M | — |
| Net loss absorbed | $14.8M | $10.9M | $4.0M | +37% |
Questions
How much did Mimedx Group's revenue grow quarter over quarter in Q2 2026?
Mimedx Group's revenue rose $5.4M (+9%) from $59.0M in Q1 2026 to $64.4M in Q2 2026.
What drove Mimedx Group's revenue change in Q2 2026?
Surgical +$2.9M (+8%); Wound +$2.4M (+11%).